Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
about
Nephrectomized and hepatectomized animal models as tools in preclinical pharmacokineticsThe use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentHigh-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinArtificial neural network models for prediction of intestinal permeability of oligopeptides.Pharmaceutical profiling case study in disruptionDrug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate.Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics.High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.Optimization of metabolic stability as a goal of modern drug design.Novel medicines marketed in the UK (1960-87).Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.Cyclodextrin-based pharmaceutics: past, present and future.Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in ratsBJCP 40th anniversary: moving forward, looking back.Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.In silico prediction of drug-binding strengths to human serum albumin.Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation.In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach.Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureusEnantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery: building chiral technology toolboxes.Bioanalysis in drug discovery and development.The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I-Comparison between Healthy Subjects and Patients with Hypertension.African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development.Computational modeling of P450s for toxicity prediction.Interspecies scaling and comparisons in drug development and toxicokinetics.Impact of preformulation on drug development.Defining "innovativeness" in drug development: a systematic review.Prediction of pharmacokinetic parameters using a genetic algorithm combined with an artificial neural network for a series of alkaloid drugs.ADME-Space: a new tool for medicinal chemists to explore ADME properties.Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles.Saffron carotenoids (crocin and crocetin) binding to human serum albumin as investigated by different spectroscopic methods and molecular docking.Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines.Design of drugs through a consideration of drug metabolism and pharmacokinetics.Nano-extrusion: a one-step process for manufacturing of solid nanoparticle formulations directly from the liquid phase
P2860
Q27027552-CA83F1E6-E06E-4B1A-8418-0E67F07C8834Q30977143-FDCAF938-01C9-45BE-9B6D-FAA0C8A97AE4Q33223310-6EB7EC70-EC56-429B-A19D-8C4CAAFB2058Q33290486-E63E6106-61C0-4C5B-8167-2183854DEB7BQ33752849-EA64FBCB-18A6-43B9-9A2B-3E1C24210284Q33946973-CFE5E344-A1C2-4104-987F-6E0661A8637DQ34260371-40521BA9-959A-4627-90E3-D4DB18E2578EQ34343253-7F7FD3B8-74C7-45EF-BD15-25B2145A3591Q34378937-0429D5AE-D7F2-4A4C-B3F7-304BE8C514B4Q34386836-978178FD-2A86-4544-913B-0D84F9044E83Q34397771-BC732627-46E5-4466-9004-1FF4F6CA6D07Q34510604-2BAB1B58-2650-43B0-882F-BC56A66AA363Q34552997-D91B60A2-5056-4892-B2A2-6D54137F8609Q34596727-ABF3BAC1-F254-4D3A-9E66-3FFFD9C7645EQ34635476-D0084467-6295-470C-A4E1-5B4C824D9945Q34819094-FAE75632-A417-447E-BA4B-EA3B9CCE4B59Q35027930-1AF24398-904A-426F-B227-750C2B04C470Q35075780-886A9FB4-704A-4BFE-A2C2-1A86F08E473FQ35088849-A1C13C6A-33F1-4AB7-9722-05BE0236C40AQ35577252-CB5798B1-C2F9-4793-BCA6-C94FDEA53B80Q36088290-B0E9E1F1-C5E4-4E40-8738-10EA8E2ED474Q36111924-14A37D08-0E94-43BB-960B-24FD3C080008Q36392641-815A1897-3156-4FA6-98C8-05E68211FC52Q36772561-8BF3694F-37A7-4A70-B5AD-0FED1DED13AAQ36855961-BDDFB996-829B-441D-B0B8-766D322B2780Q36887542-35219BB8-7280-4806-BD33-E731E950DB54Q37280941-6042CDC7-A98A-47F0-9E87-E838C7D81A24Q37714285-2AC632EC-1042-4822-9B9E-53CBE6711635Q37750885-0BA1740F-56A1-499C-A4D3-E8B7969EFD50Q37921791-EAEC62F1-30F6-4FCC-B419-BFBC39E66CDEQ38023215-4F68D1A7-00B0-4BC3-8C07-9EDA5018F327Q38093663-16530058-56DB-4D65-A43E-925792915113Q38110722-5CB22D0F-FA28-4F4A-9575-C5161474C8D0Q38258986-26D70689-4BFE-494A-ABEB-A007DB1F4E17Q38661488-E5463E64-7AA3-4B99-9340-B50A5AE129F5Q38687039-702E5912-DC4B-4EB8-B53D-884ED5AE946AQ38767937-2BF6663F-EBC5-41C3-A561-4580E36A7096Q39489705-C9BB26E4-602F-4230-8936-B3EDD0D5769BQ40600031-C1F6F675-05DE-4202-BA34-80E4B1BDEEBDQ41122558-56645611-22B2-4EA9-814F-1F5C71ACF764
P2860
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
@en
type
label
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
@en
prefLabel
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
@en
P2093
P2860
P1476
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1988.TB03318.X
P407
P577
1988-03-01T00:00:00Z